Chronic granulocytic leukemia is a malignant clonal disease of acquired hematopoietic stem cells with a possible etiology related to ionizing radiation, chemical agents, viruses and genetic factors, mainly involving the myeloid lineage. It is characterized by a persistent progressive increase in peripheral blood leukocyte count, with clinical manifestations seen as dizziness, hyperviscosemia and splenomegaly. It is classified into chronic, accelerated and acute phases, with a median survival of 3-5 years and a very poor prognosis once the disease becomes acute. Laboratory tests often show extremely active bone marrow proliferation, with granulocytes of different stages of differentiation (predominantly mature below middle childhood), some primitive cells (less than 10%), and more than 90% of slow-granulocyte BCR/ABL fusion genes (also known as Philadelphia genes) and positive chromosomes. Positive Philadelphia gene is the key to differentiate the disease from other diseases. Once the disease is diagnosed, the first treatment is with a tyrosinase inhibitor (TKI), recommended as first imatinib 400 mg qd. Hematologic, cytologic and molecular genetic responses should be monitored regularly during treatment, where cytologic responses are generally detected by FISH and molecular genetic responses are generally monitored by PCR fluorescence quantification of BCR-ABL transcript levels (IS). Patients with suboptimal treatment response and failure are evaluated by the above mentioned indexes, and BCR-ABL kinase region mutation testing is performed in a timely manner based on the evaluation of treatment compliance, patient’s drug tolerance, and combination of drugs, and second-generation TKI such as nilotinib or dasatinib is replaced when appropriate, and allo-HSCT can be considered for suitable donors. If T3151 kinase region mutation is present, both are resistant and transplantation is preferred. In Chinese medicine, it can be divided into qi stagnation and blood stasis, positive deficiency and stasis, and heat toxicity. qi stagnation and blood stasis can be seen as cavity and abdominal distension, lump under the rib cage, thin coating and stringy pulse, which belongs to liver qi stagnation, and the veins and ligaments are not in harmony. qi stagnation is not smooth blood flow, the lump is fixed, and the distension and pain is in one place. The blood can be reduced by adding safflower, angelica, curcuma longa, trigonella, and wuling fat to invigorate blood stasis; and reducing yanhuosuo, wu yao, and heliotrope to de-stasis the liver and regulate qi. It can be supplemented with Qing Dai and Xiong Huang to detoxify and dispel stasis; deficiency of stasis can be seen as thinning and deformation, yellowish face, spontaneous sweating and night sweating, wrong skin nail, dizziness and panic, less florid lips and nails, light or dark tongue, thin or sunken pulse, the disease has been prolonged and the positive energy has been weakened. The formula includes Radix et Rhizoma Ginseng, Rhizoma Atractylodis Macrocephalae, Poria, which strengthens the spleen and enhances Qi; Radix Angelicae Sinensis, Radix et Rhizoma Polygonati, Radix Aconiti, and Radix Aconiti nourish the Blood; the formula is supplemented by Radix Trigonellae, Curcuma longa, Rhizoma Safflower, and Radix et Rhizoma Yanhuo to invigorate the Blood and disperse stasis; the formula is supplemented by Radix et Rhizoma Qing Dai and Radix et Rhizoma Xiong Huang to detoxify the Blood and remove stasis. Rhinoceros Horn Dihuang Tang or Qing Ying Tang with addition and subtraction can be used. In this formula, rhinoceros horn (replaced by water buffalo horn), raw earth, tannin, red peony, clear heat and cool the blood; honeysuckle, scutellaria, and yellow lily clear heat and detoxify the toxin, accompanied by Qing Dai, white flowered snake’s tongue herb, and dragon’s quill to detoxify the toxin. Strong fever does not subside with raw gypsum, Zhi Mu and raw licorice.